Tazarotene vs Tretinoin: What the Evidence Shows in 2026

Key points

• Two 24-week trials of tazarotene 0.1% cream against tretinoin 0.05% cream for facial photodamage found tazarotene equal or somewhat better on some measures, with more early burning [8][9]. The larger was manufacturer-funded [8].
• No current US tazarotene label lists photoaging; Tazorac is labelled for plaque psoriasis and acne. The one US tretinoin label for wrinkles, Renova 0.02%, covers “mitigation (palliation) of fine facial wrinkles” [1][4].
• Pregnancy is the central safety point. US tazarotene labels list it as a contraindication, and the EMA contraindicates all topical retinoids in pregnancy and when planning one, as a precaution [1][19].
• A viral post called tazarotene the “undisputed king of anti-aging” that “deletes wrinkles”. The evidence does not support that.

What tazarotene and tretinoin are

Both are topical retinoids, related to vitamin A. Tretinoin is all-trans retinoic acid. Tazarotene is a prodrug: skin esterases convert it to tazarotenic acid, which binds the three retinoic acid receptors (RAR alpha, beta, gamma) with relative selectivity for beta and gamma [1]. Tretinoin labels say it also activates all three, but that it is “not established” whether clinical effects run through them [4][6].

Reviews describe retinoids as acting through nuclear receptors (RAR and RXR) to affect keratinocyte proliferation, collagen protection and metalloproteinases [14], with irritation the main limit, greater for tretinoin and tazarotene than for retinaldehyde or retinol [15].

What the current FDA labels say

Product	Strength	Labelled for
Tazorac cream [1]	0.05%, 0.1%	Plaque psoriasis (both); acne (0.1% only)
Tazorac gel [2]	0.05%, 0.1%	Plaque psoriasis up to 20% body surface area; 0.1% for mild to moderate facial acne
Arazlo lotion [3]	0.045%	Acne, age 9 and older
Renova cream [4]	0.02%	Adjunct for fine facial wrinkles
Retin-A cream, gel [5]	cream 0.025, 0.05, 0.1%; gel 0.01, 0.025%	Acne
Retin-A Micro gel [6]	0.04, 0.06, 0.08, 0.1%	Acne, age 12 and older
Altreno lotion [7]	0.05%	Acne, age 9 and older

All are Rx-only [1]-[7]. The Renova label states the product “DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING” and has not shown an effect on coarse wrinkles, mottled hyperpigmentation or laxity [4].

Evidence for photoaging

Head-to-head trials. Kang and colleagues (2001) randomized 349 adults with facial photodamage to four tazarotene cream strengths, vehicle or tretinoin 0.05% emollient cream for 24 weeks. Treatment success on global response was 67% (39 of 58) for tazarotene 0.1%, 52% for 0.05%, 55% (32 of 58) for tretinoin and 22% (13 of 58) for vehicle [8]. On our reading of the full text, differences among active arms were only sporadically significant. Allergan funded the study; four authors were its paid consultants and five its employees [8].

Lowe and colleagues (2004) randomized 173 subjects (157 completed) to tazarotene 0.1% or tretinoin 0.05% for 24 weeks, double-blind. All significant between-group differences favoured tazarotene, including fine wrinkling at endpoint. Tazarotene caused more burning, only in week one [9]. The abstract states no funding, and we did not verify it.

Reviews. A Cochrane review (2005, searches to June 2002) included 30 trials. Eight showed tretinoin at 0.02% or higher beat placebo (relative risk of improvement for 0.05% at 24 weeks: 1.73, 95% CI 1.39 to 2.14). One trial found 0.05% tretinoin equivalent to tazarotene 0.05% and 0.1%. Benefit and irritation rose with dose [10].

A 2025 network meta-analysis pooled 23 randomized trials (3,905 participants). Tazarotene was most consistent for coarse wrinkles, isotretinoin ranked highest for fine wrinkles, and tretinoin alone was significant for hyperpigmentation under both models. Tazarotene had the least favourable safety profile, tretinoin the most favourable among actives. The authors flag possible commercial bias, and the paper has internal mismatches (a tazarotene coarse-wrinkle odds ratio of 4.78 in text, 1.84 in a table) [11].

Seven tretinoin trials (3 to 24 months) consistently showed benefit [12]. In 25 studies comparing tretinoin with other topicals, comparators were better in 7, equal in 13 and worse in 3, mostly in low-quality studies [13].

Renova trials. The label pools five 24-week trials (324 evaluable patients on tretinoin 0.02%, 332 on vehicle). In lightly pigmented subjects, moderate fine-wrinkle improvement occurred in 10% on tretinoin versus 3% on vehicle (N=279 and 280). In 107 people with skin types IV to VI, 29% on tretinoin and 43% on vehicle had minimal or mild improvement [4].

Evidence for acne

The 2024 American Academy of Dermatology guideline strongly recommends topical retinoids for acne without ranking tazarotene against tretinoin [16]. We did not find a recent randomized head-to-head acne trial of the two.

Irritation and tolerability

The tazarotene cream label reports desquamation, dry skin, erythema and burning in 10% to 30% of acne patients, and pruritus, erythema and burning in 10% to 23% in psoriasis [1]. The Renova label reports local reactions in almost all patients; in 32% irritation was severe, led to temporary discontinuation or needed a mild corticosteroid, and about 4% stopped [4]. In Kang 2001, 59% had a treatment-related adverse event, mostly mild to moderate, and 11 of 349 withdrew for adverse events [8].

A split-face trial in healthy skin found an SPF 30 moisturizer made tretinoin 0.05% better tolerated, yet about 83% to 86% had irritation on both sides; the abstract gives no sample size or funding [17].

Pregnancy and contraindications

This is the most important safety difference between the labels.

Tazarotene. Tazorac cream and gel list pregnancy as a contraindication, call tazarotene teratogenic, and state that females of child-bearing potential should have a negative pregnancy test within two weeks before treatment and use effective contraception during it [1][2]. In animals, topical gel in rabbits at 26 times the human maximum systemic exposure produced single incidents of retinoid malformations (spina bifida, hydrocephaly, heart anomalies), and oral dosing in rats and rabbits caused malformations [1]. In trials, 13 pregnancies were reported, nine on tazarotene; one was terminated for non-medical reasons and eight delivered apparently healthy babies, a finding the label calls of unknown significance [1]. Arazlo also lists pregnancy as a contraindication [3]. There is no information on tazarotene in breast milk [1].

Tretinoin. Labels differ. Retin-A Micro and Altreno list no contraindications; they state observational data have not established a risk of major birth defects, with methodologic limits, and describe malformations in animals [6][7]. The older Retin-A label permits use in pregnancy only if benefit justifies risk, citing 30 spontaneous malformation reports over two decades (five holoprosencephaly), with no causal link established [5]. Renova says it “should not be used during pregnancy” [4].

Europe. After a review of retinoids including adapalene, tazarotene and tretinoin, the EMA said systemic absorption from topical use is negligible and harm unlikely, but topical retinoids are contraindicated in pregnancy and when planning one, as a precaution [19]. The UK Treclin (clindamycin/tretinoin) label also contraindicates pregnancy and planned pregnancy, with contraception until one month after treatment [21].

Observational data. A Nordic register cohort (2026) followed 3,869,586 infants; 2,172 had first-trimester topical retinoid exposure. Major malformations occurred in 3.3% of exposed and 3.0% of unexposed infants (adjusted risk ratio 1.1, 95% CI 0.87 to 1.38). Counting only births could understate risk, and results are not split by drug [18].

Prescription status

• US: all products above are Rx-only [1]-[7]. FDA does not approve cosmetics before sale, and says a product meant to remove wrinkles or raise collagen would be a drug; the page does not name retinol [25].
• UK: the emc search for tazarotene returned no product on 2026-11-08 [23]. A 2017 Psoriasis Association sheet described Zorac gel (0.05%, 0.1%) as prescription-only for mild to moderate plaque psoriasis [22]. We could not verify current availability. Treclin is a prescription-only acne medicine [21].
• Germany: Tretinoin and Tazaroten are both listed, without exemption, in Anlage 1 of the AMVV, the prescription-only list [20]. We could not verify current German marketing authorisations.
• EU: topical retinoids are authorised nationally in several member states [19]. Cosmetic retinol is capped by Regulation (EU) 2024/996 at 0.05% retinol equivalent in body lotion and 0.3% in other products; non-compliant products leave the market from 1 November 2025 (placing) and 1 May 2027 (availability) [24]. EUR-Lex returned no text to our recheck on 2026-11-09, so these limits are as cited from the regulation; they match the figures in the 2016 SCCS opinion discussed in our OTC retinol article.

Over-the-counter retinol and retinaldehyde

Retinol is described as a precursor of retinoic acid [28]. In a 1995 study (n=10 per comparison, 4-day occlusion), retinol caused epidermal thickening like retinoic acid with trace erythema, but no measurable retinoic acid [29]. Retinaldehyde was converted to retinoic acid in cultured keratinocytes, though in vivo models mostly produced storage esters [30]. In a 2016 study, retinol and retinoic acid both raised collagen gene expression, retinol less [28].

In a trial of 36 elderly people (mean age 87), 0.4% retinol improved fine wrinkles versus vehicle over 24 weeks [27]. A 2021 systematic review found nine vehicle-controlled OTC retinol trials: four showed no difference, and the other five had major methodological flaws [26]. A 2024 review graded retinol Grade A for anti-aging from 32 studies [31]. The tretinoin-comparison review saw some data supporting retinaldehyde as a second-line option for people who cannot tolerate tretinoin [13]. See OTC retinol vs prescription retinoids.

What the source posts claim, and how that holds up

On 2026-11-01 @Hoostethics posted that “tazarotene wipes the floor with any topical cream on the planet”, adding “combine with a solid moisteriser, ghk-cu & vitamin E. deletes wrinkles & avoids irritation simultaneously”. The 2026-10-19 tier list put tazarotene in S tier as “the undisputed king of anti-aging” and “if you only run one topical” and OTC retinol in B tier as “weak, inefficient two-step cellular conversion” [32].

• “Wipes the floor with any topical cream”: not supported. Two trials found tazarotene 0.1% equal or modestly better than tretinoin 0.05% on some measures [8][9]; Cochrane found one equivalence trial [10]; isotretinoin ranked first for fine wrinkles [11].
• “Undisputed king of anti-aging”: not supported. A 2024 review calls tretinoin the gold standard [13], tazarotene ranked worst on safety [11], and no US tazarotene label covers photoaging [1].
• “If you only run one topical for the rest of your life”: not supported. The tazarotene photodamage trials we found lasted 24 weeks [8][9]; Renova’s label says irritation effects beyond 52 weeks are unknown [4]. We found no lifetime data, and tazarotene is contraindicated in pregnancy [1].
• “Deletes wrinkles”: not supported. Gains were modest: 10% versus 3% moderate fine-wrinkle improvement in the Renova data [4], and 67% treatment success versus 22% on vehicle for tazarotene 0.1% [8].
• “Avoids irritation”: not supported. Tazarotene irritation is common [1][8]. A moisturizer reduced tretinoin irritation without eliminating it [17]. We found no trial of GHK-Cu or vitamin E for retinoid irritation (see GHK-Cu: topical vs injected evidence); that part could not be verified.
• OTC retinol is “weak, inefficient”: partly supported. Retinol is a precursor rather than the active acid, and the one direct comparison found smaller effects than retinoic acid [28]. No source we opened measured conversion efficiency in living skin, and the clinical evidence for OTC retinol is thin rather than shown null [26].

Risks and unknowns

Documented effects: burning, dryness, peeling, erythema; photosensitivity (the tazarotene label names thiazides, tetracyclines and fluoroquinolones as photosensitizers); severe irritation on eczematous skin; reports of pigment change [1][4]. Pregnancy and breastfeeding are the main population concerns. Label evidence for darker skin is small [4].

Not studied or not found: lifetime safety and efficacy, tazarotene-versus-tretinoin trials after 2004, and any benefit of adding GHK-Cu or vitamin E.

Frequently asked questions

Is tazarotene better than tretinoin for wrinkles? In two 24-week trials, tazarotene 0.1% matched or modestly beat tretinoin 0.05% on some measures, with more early burning [8][9]. A 2025 meta-analysis found it most consistent for coarse wrinkles but least favourable on safety [11].

Is tazarotene approved for anti-aging in the US? The current Tazorac labels cover plaque psoriasis and acne, not photoaging [1][2].

Are tazarotene or tretinoin allowed in pregnancy? US tazarotene labels list pregnancy as a contraindication [1][2]. US tretinoin labels range from no contraindication to “should not be used” [4][6]. The EMA contraindicates all topical retinoids in pregnancy and when planning it [19].

Sources

1. FDA via DailyMed, “Tazorac (tazarotene) cream, 0.05% and 0.1%” prescribing information, Almirall (updated 2025-11-18). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=021744d1-a6d7-4ad6-99c2-7187c24e64c6
2. FDA via DailyMed, “Tazorac (tazarotene) gel” prescribing information (updated 2025-11-18). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e4e4b81-420e-4492-8a74-80b692a80057
3. FDA via DailyMed, “Arazlo (tazarotene) lotion, 0.045%” (2023-09-27). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d941ff25-c221-4a55-8012-0dcf3bbcbbd1
4. FDA via DailyMed, “Renova (tretinoin) cream 0.02%” (2026-02-26). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f0a0e8d-1051-48a4-80c5-1bd260dd9c36
5. FDA via DailyMed, “Retin-A (tretinoin) cream, gel” (2024-05-20). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9556d73d-c573-4e0a-9feb-764ce2d1107b
6. FDA via DailyMed, “Retin-A Micro (tretinoin) gel” (2026-02-16). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ab7e0c-1437-455f-815c-98904d96a289
7. FDA via DailyMed, “Altreno (tretinoin) lotion 0.05%” (2026-10-06). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1412aba5-71aa-4cce-8db4-c189bed1852c
8. Kang S et al., “Tazarotene cream for the treatment of facial photodamage…”, Archives of Dermatology (2001). https://pubmed.ncbi.nlm.nih.gov/11735710/ ; full text https://jamanetwork.com/journals/jamadermatology/fullarticle/478614
9. Lowe NJ et al., “Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream…”, J Cosmet Laser Ther (2004). https://pubmed.ncbi.nlm.nih.gov/15203997/
10. Samuel M et al., “Interventions for photodamaged skin”, Cochrane Database Syst Rev (2005). https://pubmed.ncbi.nlm.nih.gov/15674885/
11. Lin L et al., “Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis”, Scientific Reports (2025-07-24). https://pmc.ncbi.nlm.nih.gov/articles/PMC12289910
12. Sitohang IBS et al., “Topical tretinoin for treating photoaging: a systematic review of randomized controlled trials”, Int J Womens Dermatol (2022). https://pubmed.ncbi.nlm.nih.gov/35620028/
13. Siddiqui et al., “Comparing tretinoin to other topical therapies in the treatment of skin photoaging: a systematic review”, Am J Clin Dermatol (2024). https://pubmed.ncbi.nlm.nih.gov/39348007/
14. Zasada M, Budzisz E., “Retinoids: active molecules influencing skin structure formation…”, Postepy Dermatol Alergol (2019). https://pubmed.ncbi.nlm.nih.gov/31616211/
15. Mukherjee S et al., “Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety”, Clin Interv Aging (2006). https://pubmed.ncbi.nlm.nih.gov/18046911/
16. Reynolds RV et al., “Guidelines of care for the management of acne vulgaris”, J Am Acad Dermatol (2024). https://pubmed.ncbi.nlm.nih.gov/38300170/
17. Schorr E et al., “Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves tolerability of topical tretinoin 0.05%”, J Drugs Dermatol (2012). https://pubmed.ncbi.nlm.nih.gov/23135655/
18. Refsum et al., “Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies: a Nordic cohort study”, Br J Dermatol (2026). https://pubmed.ncbi.nlm.nih.gov/41365815/
19. European Medicines Agency, “Updated measures for pregnancy prevention during retinoid use” (2018-03-23). https://www.ema.europa.eu/en/news/updated-measures-pregnancy-prevention-during-retinoid-use
20. Germany, “Arzneimittelverschreibungsverordnung (AMVV), Anlage 1”. https://www.gesetze-im-internet.de/amvv/anlage_1.html
21. electronic Medicines Compendium, “Treclin 1%/0.025% w/w gel” SmPC (revised February 2026). https://www.medicines.org.uk/emc/product/5371/smpc
22. Psoriasis Association, “Tazarotene (Zorac)” information sheet (file dated 2017-04-05). https://psoriasisuk.org.uk/media/InformationSheets/Tazarotene.pdf
23. electronic Medicines Compendium, search for “tazarotene” (checked 2026-11-08; no results). https://www.medicines.org.uk/emc/search?q=tazarotene
24. European Commission, Regulation (EU) 2024/996 of 3 April 2024 (OJ 2024-04-04). https://eur-lex.europa.eu/eli/reg/2024/996/oj/eng
25. FDA, “Wrinkle Treatments and Other Anti-aging Products” (page current as of 2022-02-25). https://www.fda.gov/cosmetics/cosmetic-products/wrinkle-treatments-and-other-anti-aging-products
26. Spierings NMK, “Evidence for the efficacy of over-the-counter vitamin A cosmetic products in the improvement of facial skin aging: a systematic review”, J Clin Aesthet Dermatol (2021). https://pubmed.ncbi.nlm.nih.gov/34980969/
27. Kafi R et al., “Improvement of naturally aged skin with vitamin A (retinol)”, Arch Dermatol (2007). https://pubmed.ncbi.nlm.nih.gov/17515510/
28. Kong R et al., “A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin”, J Cosmet Dermatol (2016). https://pubmed.ncbi.nlm.nih.gov/26578346/
29. Kang S et al., “Application of retinol to human skin in vivo induces epidermal hyperplasia… but without measurable retinoic acid levels or irritation”, J Invest Dermatol (1995). https://pubmed.ncbi.nlm.nih.gov/7561157/
30. Sorg O et al., “Metabolism of topical retinaldehyde”, Dermatology (1999). https://pubmed.ncbi.nlm.nih.gov/10473954/
31. Lau et al., “Cosmeceuticals for antiaging: a systematic review of safety and efficacy”, Arch Dermatol Res (2024). https://pubmed.ncbi.nlm.nih.gov/38758222/
32. @Hoostethics on X, post of 2026-11-01 (id 2116976569034092805) quoting the poster’s topical skincare tier list of 2026-10-19; text read through the fxtwitter mirror. https://x.com/Hoostethics/status/2116976569034092805 ; original topical skincare tier list of 2026-10-19: https://x.com/Hoostethics/status/2112214865779806696

This article is information, not medical advice.